Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,310

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation

Open access
Authors/Task Force Members, Van de Werf, Frans, Bax, Jeroen, Betriu, Amadeo, Blomstrom-Lundqvist, Carina, Crea, Filippo, Falk, Volkmar, Filippatos, Gerasimos, Fox, Keith, Huber, Kurt, Kastrati, Adnan, Rosengren, Annika, Steg, P. Gabriel, Tubaro, Marco, Verheugt, Freek, Weidinger, Franz, Weis, Michael, ESC Committee for Practice Guidelines (CPG), Vahanian, Alec, Camm, John, De Caterina, Raffaele, Dean, Veronica, Dickstein, Kenneth, Filippatos, Gerasimos, Funck-Brentano, Christian, Hellemans, Irene, Kristensen, Steen Dalby, McGregor, Keith, Sechtem, Udo, Silber, Sigmund, Tendera, Michal, Widimsky, Petr, Zamorano, José Luis, Document Reviewers, Silber, Sigmund, Aguirre, Frank V., Al-Attar, Nawwar, Alegria, Eduardo, Andreotti, Felicita, Benzer, Werner, Breithardt, Ole, Danchin, Nicholas, Mario, Carlo Di, Dudek, Dariusz, Gulba, Dietrich, Halvorsen, Sigrun, Kaufmann, Philipp, Kornowski, Ran, Lip, Gregory Y. H., Rutten, Frans·2008·European Heart Journal
DOI 10.1093/eurheartj/ehn416
Open this paper in CoChat — free account

Abstract

The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer.It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehn416

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 237

  1. Thygesen, 2007, Universal definition of myocardial infarction, Eur Heart J, 28, 2525, 10.1093/eurheartj/ehm355 · DOI · Paper page
  2. Bassand, 2007, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes, Eur Heart J, 28, 1598, 10.1093/eurheartj/ehm161 · DOI · Paper page
  3. Fuster, 2005, Atherothrombosis and high-risk plaque: part I: evolving concepts, J Am Coll Cardiol, 46, 937, 10.1016/j.jacc.2005.03.074 · DOI · Paper page
  4. Rodriguez-Granillo, 2006, Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis, Eur Heart J, 27, 1921, 10.1093/eurheartj/ehl104 · DOI
  5. Detrano, 2008, Coronary calcium as a predictor of coronary events in four racial or ethnic groups, N Engl J Med, 358, 1336, 10.1056/NEJMoa072100 · DOI · Paper page
  6. Rittersma, 2005, Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention, Circulation, 111, 1160, 10.1161/01.CIR.0000157141.00778.AC · DOI · Paper page
  7. Lee, 2005, Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes, Blood, 105, 526, 10.1182/blood-2004-03-1106 · DOI
  8. Stone, 2004, Triggering myocardial infarction, N Engl J Med, 351, 1716, 10.1056/NEJMp048245 · DOI
  9. Davies, 2000, The pathophysiology of acute coronary syndromes, Heart, 83, 361, 10.1136/heart.83.3.361 · DOI · Paper page
  10. Keeley, 2006, Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials, Lancet, 367, 579, 10.1016/S0140-6736(06)68148-8 · DOI · Paper page
  11. Tunstall-Pedoe, 1999, Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease, Lancet, 353, 1547, 10.1016/S0140-6736(99)04021-0 · DOI · Paper page
  12. Goldberg, 2006, Trends in community mortality due to coronary heart disease, Am Heart J, 151, 501, 10.1016/j.ahj.2005.04.024 · DOI
  13. Armstrong, 2007, Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial, JAMA, 297, 43, 10.1001/jama.297.1.43 · DOI · Paper page
  14. 2006, Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial, Lancet, 367, 569, 10.1016/S0140-6736(06)68147-6 · DOI · Paper page
  15. Fox, 2006, Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE), BMJ, 333, 1091, 10.1136/bmj.38985.646481.55 · DOI · Paper page
  16. Le May, 2008, A citywide protocol for primary PCI in ST-segment elevation myocardial infarction, N Engl J Med, 358, 231, 10.1056/NEJMoa073102 · DOI · Paper page
  17. Bassand, 2005, Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology, Eur Heart J, 26, 2733, 10.1093/eurheartj/ehi673 · DOI
  18. Lee, 1995, Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators, Circulation, 91, 1659, 10.1161/01.CIR.91.6.1659 · DOI · Paper page
  19. Morrow, 2000, TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy, Circulation, 102, 2031, 10.1161/01.CIR.102.17.2031 · DOI · Paper page
  20. European Resuscitation Council, 2005, European Resuscitation Council guidelines for resuscitation 2005, Resuscitation, 67, S3, 10.1016/j.resuscitation.2005.10.002 · DOI
  21. Schomig, 2005, Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial, JAMA, 293, 2865, 10.1001/jama.293.23.2865 · DOI · Paper page
  22. Hochman, 2006, Coronary intervention for persistent occlusion after myocardial infarction, N Engl J Med, 355, 2395, 10.1056/NEJMoa066139 · DOI · Paper page
  23. Menon, 2008, Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial, Eur Heart J, 10.1093/eurheartj/ehn486 · DOI
  24. Silber, 2005, Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology, Eur Heart J, 26, 804, 10.1093/eurheartj/ehi138 · DOI · Paper page
  25. Canto, 2000, The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators, N Engl J Med, 342, 1573, 10.1056/NEJM200005253422106 · DOI · Paper page
  26. Spaulding, 2006, Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry, Eur Heart J, 27, 1054, 10.1093/eurheartj/ehi843 · DOI
  27. Keeley, 2003, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials, Lancet, 361, 13, 10.1016/S0140-6736(03)12113-7 · DOI · Paper page
  28. Grines, 1999, Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group, N Engl J Med, 341, 1949, 10.1056/NEJM199912233412601 · DOI · Paper page
  29. Stone, 2002, Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction, N Engl J Med, 346, 957, 10.1056/NEJMoa013404 · DOI · Paper page
  30. Spaulding, 2006, Sirolimus-eluting versus uncoated stents in acute myocardial infarction, N Engl J Med, 355, 1093, 10.1056/NEJMoa062006 · DOI · Paper page
  31. Laarman, 2006, Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention, N Engl J Med, 355, 1105, 10.1056/NEJMoa062598 · DOI · Paper page
  32. Kastrati, 2007, Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction, Eur Heart J, 28, 2706, 10.1093/eurheartj/ehm402 · DOI · Paper page
  33. De Luca, 2003, Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty, J Am Coll Cardiol, 42, 991, 10.1016/S0735-1097(03)00919-7 · DOI · Paper page
  34. Nallamothu, 2007, Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events, Heart, 93, 1552, 10.1136/hrt.2006.112847 · DOI
  35. Nallamothu, 2003, Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?, Am J Cardiol, 92, 824, 10.1016/S0002-9149(03)00891-9 · DOI · Paper page
  36. Betriu, 2005, Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis, Am J Cardiol, 95, 100, 10.1016/j.amjcard.2004.08.069 · DOI
  37. Nallamothu, 2004, Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment?, Am J Cardiol, 94, 772, 10.1016/j.amjcard.2004.05.064 · DOI
  38. Boersma, 2006, Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients, Eur Heart J, 27, 779, 10.1093/eurheartj/ehi810 · DOI · Paper page
  39. Pinto, 2006, Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy, Circulation, 114, 2019, 10.1161/CIRCULATIONAHA.106.638353 · DOI · Paper page
  40. Kastrati, 2004, A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy, J Am Coll Cardiol, 43, 734, 10.1016/j.jacc.2003.07.054 · DOI
  41. Hochman, 1999, Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock, N Engl J Med, 341, 625, 10.1056/NEJM199908263410901 · DOI · Paper page
  42. Ellis, 2008, Facilitated PCI in patients with ST-elevation myocardial infarction, N Engl J Med, 358, 2205, 10.1056/NEJMoa0706816 · DOI · Paper page
  43. Van't Hof, 2008, Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial, Lancet, 372, 537, 10.1016/S0140-6736(08)61235-0 · DOI · Paper page
  44. Gershlick, 2005, Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction, N Engl J Med, 353, 2758, 10.1056/NEJMoa050849 · DOI · Paper page
  45. Wijeysundera, 2007, Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials, J Am Coll Cardiol, 49, 422, 10.1016/j.jacc.2006.09.033 · DOI
  46. Gislason, 2006, Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nosteroidal antiinflammatory drugs after acute myocardial infarction, Circulation, 113, 2906, 10.1161/CIRCULATIONAHA.106.616219 · DOI · Paper page
  47. Antman, 2007, Use of nonsteroidal antiinflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association, Circulation, 115, 326, 10.1161/CIRCULATIONAHA.106.181424 · DOI · Paper page
  48. Fox, 2004, Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial, Circulation, 110, 1202, 10.1161/01.CIR.0000140675.85342.1B · DOI · Paper page
  49. Beinart, 2005, Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial, J Am Coll Cardiol, 46, 761, 10.1016/j.jacc.2005.03.073 · DOI
  50. Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522 · DOI · Paper page
  51. von Beckerath, 2005, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 · DOI · Paper page
  52. Montalescot, 2006, A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial, J Am Coll Cardiol, 48, 931, 10.1016/j.jacc.2006.04.090 · DOI · Paper page
  53. De Luca, 2005, Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials, JAMA, 293, 1759, 10.1001/jama.293.14.1759 · DOI · Paper page
  54. Stone, 2008, Bivalirudin during primary PCI in acute myocardial infarction, N Engl J Med, 358, 2218, 10.1056/NEJMoa0708191 · DOI · Paper page
  55. Yusuf, 2006, Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial, JAMA, 295, 1519, 10.1001/jama.295.13.joc60038 · DOI · Paper page
  56. Burzotta, 2008, Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials, Int J Cardiol, 123, 313, 10.1016/j.ijcard.2006.12.018 · DOI
  57. Svilaas, 2008, Thrombus aspiration during primary percutaneous coronary intervention, N Engl J Med, 358, 557, 10.1056/NEJMoa0706416 · DOI · Paper page
  58. Vlaar, 2008, Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study, Lancet, 371, 1915, 10.1016/S0140-6736(08)60833-8 · DOI · Paper page
  59. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients, Lancet, 343, 311, 10.1016/S0140-6736(94)91161-4 · DOI · Paper page
  60. White, 2000, Thrombolytic therapy in the elderly, Lancet, 356, 2028, 10.1016/S0140-6736(00)03397-3 · DOI
  61. Morrison, 2000, Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis, JAMA, 283, 2686, 10.1001/jama.283.20.2686 · DOI · Paper page
  62. Boersma, 1996, Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour, Lancet, 348, 771, 10.1016/S0140-6736(96)02514-7 · DOI · Paper page
  63. Steg, 2003, Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial, Circulation, 108, 2851, 10.1161/01.CIR.0000103122.10021.F2 · DOI · Paper page
  64. Danchin, 2008, Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI), Circulation, 118, 268, 10.1161/CIRCULATIONAHA.107.762765 · DOI · Paper page
  65. Kalla, 2006, Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry), Circulation, 113, 2398, 10.1161/CIRCULATIONAHA.105.586198 · DOI · Paper page
  66. Gore, 1995, Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries, Circulation, 92, 2811, 10.1161/01.CIR.92.10.2811 · DOI
  67. Van de Werf, 1999, Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial, Lancet, 354, 716, 10.1016/S0140-6736(99)07403-6 · DOI · Paper page
  68. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators, 1997, A comparsion of reteplase with alteplase for acute myocardial infarction, N Engl J Med, 337, 1118, 10.1056/NEJM199710163371603 · DOI · Paper page
  69. Berkowitz, 1997, Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators, Circulation, 95, 2508, 10.1161/01.CIR.95.11.2508 · DOI · Paper page
  70. The GUSTO Investigators, 1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med, 329, 673, 10.1056/NEJM199309023291001 · DOI · Paper page
  71. Böttiger, 2008, Thrombolysis during resuscitation for out-of-hospital cardiac arrest, N Engl J Med, 10.1056/NEJMoa070570 · DOI · Paper page
  72. Barbash, 2001, Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies, Circulation, 103, 954, 10.1161/01.CIR.103.7.954 · DOI
  73. Di Mario, 2008, Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial, Lancet, 371, 559, 10.1016/S0140-6736(08)60268-8 · DOI · Paper page
  74. Fernandez-Aviles, 2007, Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial, Eur Heart J, 28, 949, 10.1093/eurheartj/ehl461 · DOI
  75. Le May, 2005, Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study), J Am Coll Cardiol, 46, 417, 10.1016/j.jacc.2005.04.042 · DOI · Paper page
  76. Fernandez-Aviles, 2004, Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial, Lancet, 364, 1045, 10.1016/S0140-6736(04)17059-1 · DOI · Paper page
  77. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, 2005, Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X · DOI · Paper page
  78. Topol EJ for The GUSTO V investigators, 2001, Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial, Lancet, 357, 1905, 10.1016/S0140-6736(00)05059-5 · DOI · Paper page
  79. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators, 2001, Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction, Lancet, 358, 605, 10.1016/S0140-6736(01)05775-0 · DOI · Paper page
  80. de Bono, 1992, Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial, Br Heart J, 67, 122, 10.1136/hrt.67.2.122 · DOI · Paper page
  81. The GUSTO Angiographic Investigators, 1993, The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction, N Engl J Med, 329, 1615, 10.1056/NEJM199311253292204 · DOI · Paper page
  82. Thompson, 1991, A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 h after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group, Circulation, 83, 1534, 10.1161/01.CIR.83.5.1534 · DOI
  83. Granger, 1996, Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial, Circulation, 93, 870, 10.1161/01.CIR.93.5.870 · DOI · Paper page
  84. Wallentin, 2003, Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction, Circulation, 108, 135, 10.1161/01.CIR.0000081659.72985.A8 · DOI · Paper page
  85. Giraldez, 2007, Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis, Eur Heart J, 28, 1566, 10.1093/eurheartj/ehm179 · DOI
  86. White, 2007, Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25, Eur Heart J, 28, 1066, 10.1093/eurheartj/ehm081 · DOI
  87. Peters, 2008, The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial, Eur Heart J, 29, 324, 10.1093/eurheartj/ehm616 · DOI
  88. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators, 2001, Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving flbrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial, Lancet, 358, 1855, 10.1016/S0140-6736(01)06887-8 · DOI · Paper page
  89. Cohen, 2003, The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial, J Am Coll Cardiol, 42, 1348, 10.1016/S0735-1097(03)01040-4 · DOI
  90. Oldgren, 2007, Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment, Eur Heart J, 29, 315, 10.1093/eurheartj/ehm578 · DOI
  91. Mehta, 2005, Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial, JAMA, 293, 437, 10.1001/jama.293.4.437 · DOI · Paper page
  92. Oldgren, 2008, Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment, Eur Heart J, 29, 315, 10.1093/eurheartj/ehm578 · DOI
  93. Ito, 1992, Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction, Circulation, 85, 1699, 10.1161/01.CIR.85.5.1699 · DOI · Paper page
  94. Ito, 1996, Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction, Circulation, 93, 223, 10.1161/01.CIR.93.2.223 · DOI · Paper page
  95. Kelly, 2004, The no-reflow phenomenon in coronary arteries, J Thromb Haemost, 2, 1903, 10.1111/j.1538-7836.2004.00898.x · DOI
  96. Maes, 1995, Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up, Circulation, 92, 2072, 10.1161/01.CIR.92.8.2072 · DOI
  97. Kaul, 2004, Microvasculature in acute myocardial ischemia: part II: evolving concepts in pathophysiology, diagnosis, and treatment, Circulation, 109, 310, 10.1161/01.CIR.0000111583.89777.F9 · DOI
  98. Yellon, 2007, Myocardial reperfusion injury, N Engl J Med, 357, 1121, 10.1056/NEJMra071667 · DOI · Paper page
  99. Sorajja, 2005, Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction, Eur Heart J, 26, 667, 10.1093/eurheartj/ehi167 · DOI
  100. Galiuto, 2007, Functional and structural correlates of persistent ST elevation after acute myocardial infarction successfully treated by percutaneous coronary intervention, Heart, 93, 1376, 10.1136/hrt.2006.105320 · DOI
  101. Ito, 2006, No-reflow phenomenon and prognosis in patients with acute myocardial infarction, Nat Clin Pract Cardiovas Med, 3, 499, 10.1038/ncpcardio0632 · DOI
  102. Iwakura, 1996, Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction, Circulation, 94, 1269, 10.1161/01.CIR.94.6.1269 · DOI
  103. Sheehan, 1987, The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial, Circulation, 75, 817, 10.1161/01.CIR.75.4.817 · DOI · Paper page
  104. van ‘t Hof, 1998, Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group, Circulation, 97, 2302, 10.1161/01.CIR.97.23.2302 · DOI · Paper page
  105. Eeckhout, 2001, The coronary no-reflow phenomenon: a review of mechanisms and therapies, Eur Heart J, 22, 729, 10.1053/euhj.2000.2172 · DOI · Paper page
  106. Ross, 2005, A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II), J Am Coll Cardiol, 45, 1775, 10.1016/j.jacc.2005.02.061 · DOI · Paper page
  107. de Lemos, 2000, Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial, Circulation, 101, 239, 10.1161/01.CIR.101.3.239 · DOI
  108. Petronio, 2003, Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty, Eur Heart J, 24, 67, 10.1016/S0195-668X(02)00324-1 · DOI
  109. Thielmann, 2006, Prognostic value of preoperative cardiac troponin I in patients undergoing emergency coronary artery bypass surgery with non-ST-elevation or ST-elevation acute coronary syndromes, Circulation, 114, I448, 10.1161/CIRCULATIONAHA.105.001057 · DOI
  110. Lee, 2003, Appropriate timing of surgical intervention after transmural acute myocardial infarction, J Thorac Cardiovasc Surg, 125, 115, 10.1067/mtc.2003.75 · DOI
  111. Nicod, 1988, Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction, Am J Cardiol, 61, 1165, 10.1016/0002-9149(88)91148-4 · DOI
  112. Dickstein, 2008, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008, Eur Heart J, 29, 2388, 10.1093/eurheartj/ehn309 · DOI · Paper page
  113. Hochman, 2001, One-year survival following early revascularization for cardiogenic shock, JAMA, 285, 190, 10.1001/jama.285.2.190 · DOI · Paper page
  114. Leshnower, 2006, Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock, Ann Thorac Surg, 81, 1365, 10.1016/j.athoracsur.2005.11.040 · DOI
  115. Tayara, 2006, Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment, J Heart Lung Transplant, 25, 504, 10.1016/j.healun.2005.10.011 · DOI
  116. Thiele, 2007, Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock, Eur Heart J, 28, 2057, 10.1093/eurheartj/ehm191 · DOI
  117. Cummings, 1989, Correlates of survival in patients with postinfarction ventricular septal defect, Ann Thorac Surg, 47, 824, 10.1016/0003-4975(89)90012-X · DOI
  118. Lemery, 1992, Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention, Am J Cardiol, 70, 147, 10.1016/0002-9149(92)91266-7 · DOI
  119. Topaz, 1992, Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management, Am J Med, 93, 683, 10.1016/0002-9343(92)90203-N · DOI
  120. Chevalier, 2004, Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation, Eur J Cardiothorac Surg, 26, 330, 10.1016/j.ejcts.2004.04.027 · DOI
  121. Chen, 2002, Mitral valve surgery for acute papillary muscle rupture following myocardial infarction, Heart Valve Dis, 11, 27
  122. Newby, 1998, Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators, Circulation, 98, 2567, 10.1161/01.CIR.98.23.2567 · DOI
  123. Henkel, 2006, Ventricular arrhythmias after acute myocardial infarction: a 20-year community study, Am Heart J, 151, 806, 10.1016/j.ahj.2005.05.015 · DOI
  124. Huikuri, 2001, Sudden death due to cardiac arrhythmias, N Engl J Med, 345, 1473, 10.1056/NEJMra000650 · DOI · Paper page
  125. Gardner, 2000, Nonsustained ventricular tachycardia in 193 U.S. military aviators: long-term follow-up, Aviat Space Environ Med, 71, 783
  126. Hjalmarson, 1997, Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period, Am J Cardiol, 80, 35J, 10.1016/S0002-9149(97)00837-0 · DOI
  127. Zipes, 2006, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, Eur Heart J, 27, 2099, 10.1093/eurheartj/ehl199 · DOI · Paper page
  128. Rathore, 2000, Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes, Circulation, 101, 969, 10.1161/01.CIR.101.9.969 · DOI · Paper page
  129. Goldstein, 2005, Patterns of coronary compromise leading to bradyarrhythmias and hypotension in inferior myocardial infarction, Coron Artery Dis, 16, 265, 10.1097/00019501-200508000-00002 · DOI
  130. Meine, 2005, Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy, Am Heart J, 149, 670, 10.1016/j.ahj.2004.07.035 · DOI
  131. Newby, 1996, Incidence and clinical relevance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy, Circulation, 94, 2424, 10.1161/01.CIR.94.10.2424 · DOI
  132. Gregoratos, 2002, ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines), Circulation, 106, 2145, 10.1161/01.CIR.0000035996.46455.09 · DOI · Paper page
  133. Vardas, 2007, Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association, Eur Heart J, 28, 2256, 10.1093/eurheartj/ehm305 · DOI · Paper page
  134. Roberts, 1991, Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study, Circulation, 83, 422, 10.1161/01.CIR.83.2.422 · DOI · Paper page
  135. Van de Werf, 1993, Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy, J Am Coll Cardiol, 22, 407, 10.1016/0735-1097(93)90044-2 · DOI
  136. Pfisterer, 1998, Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries, J Am Coll Cardiol, 32, 634, 10.1016/S0735-1097(98)00279-4 · DOI
  137. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, 2005, Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1622, 10.1016/S0140-6736(05)67661-1 · DOI · Paper page
  138. GISSI-3, 1994, Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, Lancet, 343, 1115
  139. ISIS-4, 1995, A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group, Lancet, 345, 669, 10.1016/S0140-6736(95)90865-X · DOI · Paper page
  140. Yusuf, 1991, Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies, Am J Cardiol, 67, 1295, 10.1016/0002-9149(91)90944-G · DOI · Paper page
  141. Chinese Cardiac Study Collaborative Group, 1995, Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac study (CCS-1), Lancet, 345, 686, 10.1016/S0140-6736(95)90866-8 · DOI · Paper page
  142. Pfeffer, 1995, When a question has an answer: rationale for our early termination of the HEART trial, Am J Cardiol, 75, 1173, 10.1016/S0002-9149(99)80753-X · DOI
  143. Brodie, 2007, Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction versus left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction, Am J Cardiol, 99, 431, 10.1016/j.amjcard.2006.09.091 · DOI
  144. Zeymer, 1998, Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis, J Am Coll Cardiol, 32, 876, 10.1016/S0735-1097(98)00344-1 · DOI
  145. Mak, 1997, Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries, J Am Coll Cardiol, 30, 171, 10.1016/S0735-1097(97)00118-6 · DOI · Paper page
  146. McGuire, 2000, Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators, Eur Heart J, 21, 1750, 10.1053/euhj.2000.2317 · DOI
  147. Laakso, 2001, Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention, J Intern Med, 249, 225, 10.1046/j.1365-2796.2001.00789.x · DOI
  148. Roe, 2006, The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes, Am Heart J, 151, 1205, 10.1016/j.ahj.2005.08.006 · DOI
  149. Norhammar, 2003, Under utilisation of evidence-based treatment partially explains the unfavourable prognosis in diabetic patients with acute myocardial infarction, Eur Heart J, 24, 838, 10.1016/S0195-668X(02)00828-X · DOI
  150. Mahaffey, 1997, Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries, J Am Coll Cardiol, 30, 1606, 10.1016/S0735-1097(97)00394-X · DOI
  151. Anselmino, 2007, Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart, Eur J Cardiovasc Prev Rehabil, 14, 28, 10.1097/01.hjr.0000199496.23838.83 · DOI
  152. Malmberg, 1989, Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies, Eur Heart J, 10, 423, 10.1093/oxfordjournals.eurheartj.a059505 · DOI
  153. Stenestrand, 2001, Early statin treatment following acute myocardial infarction and 1-year survival, JAMA, 285, 430, 10.1001/jama.285.4.430 · DOI · Paper page
  154. Cao, 2005, Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus, Am J Cardiol, 96, 183, 10.1016/j.amjcard.2005.03.040 · DOI
  155. Malmberg, 1999, Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study, Circulation, 99, 2626, 10.1161/01.CIR.99.20.2626 · DOI · Paper page
  156. Malmberg, 1995, Randomized trial of insulin–glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year, J Am Coll Cardiol, 26, 57, 10.1016/0735-1097(95)00126-K · DOI · Paper page
  157. Malmberg, 1997, Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group, BMJ, 314, 1512, 10.1136/bmj.314.7093.1512 · DOI · Paper page
  158. Malmberg, 2005, Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity, Eur Heart J, 26, 650, 10.1093/eurheartj/ehi199 · DOI · Paper page
  159. Deedwania, 2008, Hyperglycemia and acute coronary syndrome. A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism, Circulation, 117, 1610, 10.1161/CIRCULATIONAHA.107.188629 · DOI · Paper page
  160. Svensson, 2005, Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events, Eur Heart J, 26, 1245, 10.1093/eurheartj/ehi230 · DOI · Paper page
  161. Sarnak, 2003, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention, Hypertension, 42, 1050, 10.1161/01.HYP.0000102971.85504.7c · DOI · Paper page
  162. Anavekar, 2004, Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, N Engl J Med, 351, 1285, 10.1056/NEJMoa041365 · DOI · Paper page
  163. Assali, 2007, The impact of renal insufficiency on patients’ outcomes in emergent angioplasty for acute myocardial infarction, Catheter Cardiovasc Interv, 69, 395, 10.1002/ccd.20939 · DOI
  164. Behar, 1994, Prognosis of early versus late ventricular fibrillation complicating acute myocardial infarction, Int J Cardiol, 45, 191, 10.1016/0167-5273(94)90165-1 · DOI
  165. Brugada, 2001, Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome, J Am Coll Cardiol, 37, 529, 10.1016/S0735-1097(00)01133-5 · DOI
  166. Natale, 1994, Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice?, J Cardiovasc Electrophysiol, 5, 988, 10.1111/j.1540-8167.1994.tb01140.x · DOI
  167. Lee, 2003, Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis, J Am Coll Cardiol, 41, 1573, 10.1016/S0735-1097(03)00253-5 · DOI
  168. Ezekowitz, 2003, Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials, Ann Intern Med, 138, 445, 10.7326/0003-4819-138-6-200303180-00007 · DOI · Paper page
  169. Sarter, 1996, What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction?, J Am Coll Cardiol, 28, 122, 10.1016/0735-1097(96)00123-4 · DOI
  170. Fox, 2007, Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE), Heart, 93, 177, 10.1136/hrt.2005.084830 · DOI · Paper page
  171. Sitt, 2008, Lipid levels after acute coronary syndromes, J Am Coll Cardiol, 51, 1440, 10.1016/j.jacc.2007.11.075 · DOI
  172. Schinkel, 2007, Hibernating myocardium: diagnosis and patient outcomes, Curr Probl Cardiol, 32, 375, 10.1016/j.cpcardiol.2007.04.001 · DOI
  173. Chow, 2006, Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy, J Am Coll Cardiol, 47, 1820, 10.1016/j.jacc.2005.11.079 · DOI
  174. Graham, 2007, European guidelines on cardiovascular disease prevention in clinical practice: executive summary, Eur Heart J, 28, 2375, 10.1093/eurheartj/ehm316 · DOI · Paper page
  175. Jolly, The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation, Heart
  176. Giannuzzi, 2003, European Society of Cardiology. Physical activity for primary and secondary prevention. Position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology, Eur Heart J, 24, 1273, 10.1016/S0195-668X(03)00198-2 · DOI · Paper page
  177. Rees, 2004, Psychological interventions for coronary heart disease, Cochrane Database Syst Rev, (2), CD002902
  178. Nicholson, 2006, Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies, Eur Heart J, 27, 2763, 10.1093/eurheartj/ehl338 · DOI · Paper page
  179. O'Connor, 1989, An overview of randomized trials of rehabilitation with exercise after myocardial infarction, Circulation, 80, 234, 10.1161/01.CIR.80.2.234 · DOI · Paper page
  180. Buch, 2007, Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002, Heart, 93, 210, 10.1136/hrt.2006.092213 · DOI
  181. Rosengren, 2005, Cardiovascular risk factors and clinical presentation in acute coronary syndromes, Heart, 91, 1141, 10.1136/hrt.2004.051508 · DOI
  182. Aberg, 1983, Cessation of smoking after myocardial infarction. Effects on mortality after 10 years, Br Heart J, 49, 416, 10.1136/hrt.49.5.416 · DOI
  183. Meine, 2005, Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes, Am J Cardiol, 95, 976, 10.1016/j.amjcard.2004.12.039 · DOI
  184. Mead, 2006, Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease—evidence from systematic reviews of randomized controlled trials (second update, January 2006), J Hum Nutr Diet, 19, 401, 10.1111/j.1365-277X.2006.00726.x · DOI
  185. GISSI Prevenzione Investigators, 1999, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravivvenza nell'Infarcto miocardico, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5 · DOI · Paper page
  186. Hooper, 2006, Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review, BMJ, 332, 752, 10.1136/bmj.38755.366331.2F · DOI · Paper page
  187. Rosengren, 2004, Sex, age, and clinical presentation of acute coronary syndromes, Eur Heart J, 25, 663, 10.1016/j.ehj.2004.02.023 · DOI
  188. Taylor, 2004, Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials, Am J Med, 116, 682, 10.1016/j.amjmed.2004.01.009 · DOI · Paper page
  189. Antithrombotic Trialists' Collaboration, 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
  190. Smith, 1990, The effect of warfarin on mortality and reinfarction after myocardial infarction, N Engl J Med, 323, 147, 10.1056/NEJM199007193230302 · DOI · Paper page
  191. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group, 1994, Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infraction, Lancet, 343, 499
  192. Andreotti, 2006, Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients, Eur Heart J, 27, 519, 10.1093/eurheartj/ehi485 · DOI · Paper page
  193. Karjalainen, 2007, Safety and efficacy of combined antiplatelet–warfarin therapy after coronary stenting, Eur Heart J, 28, 726, 10.1093/eurheartj/ehl488 · DOI · Paper page
  194. Rubboli, 2005, Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting, Cardiology, 104, 101, 10.1159/000086918 · DOI
  195. Nguyen, 2007, Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?, Eur Heart J, 28, 1717, 10.1093/eurheartj/ehm186 · DOI
  196. The Danish Study Group on Verapamil in Myocardial Infarction, 1990, Effect of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II), Am J Cardiol, 66, 779, 10.1016/0002-9149(90)90351-Z · DOI · Paper page
  197. The Multicenter Diltiazem Postinfarction Trial Research Group, 1988, The effect of diltiazem on mortality and reinfarction after myocardial infarction, N Engl J Med, 319, 385, 10.1056/NEJM198808183190701 · DOI · Paper page
  198. Boden, 2000, Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT), Lancet, 355, 1751, 10.1016/S0140-6736(00)02262-5 · DOI
  199. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821
  200. Ambrosioni, 1995, The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators, N Engl J Med, 332, 80, 10.1056/NEJM199501123320203 · DOI · Paper page

200 of 237 shown

Cited by

See all 2,310

Metadata

Authors
Authors/Task Force Members, Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., Kastrati, A., Rosengren, A., Steg, P. G., Tubaro, M., Verheugt, F., Weidinger, F., Weis, M., ESC Committee for Practice Guidelines (CPG), Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Reviewers, D., Silber, S., Aguirre, F. V., Al-Attar, N., Alegria, E., Andreotti, F., Benzer, W., Breithardt, O., Danchin, N., Mario, C. D., Dudek, D., Gulba, D., Halvorsen, S., Kaufmann, P., Kornowski, R., Lip, G. Y. H., & Rutten, F.
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2008-12-01
Volume
29
Issue
23
Pages
2909-2945
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehn416
OpenAlex
W2117254307
Cited by
2,310
References
20
FWCI
213.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.